This web page was created programmatically, to learn the article in its authentic location you possibly can go to the hyperlink bellow:
https://www.nature.com/articles/s41586-026-10672-8
and if you wish to take away this text from our website please contact us
Younossi, Z. M., Kalligeros, M. & Henry, L. Epidemiology of metabolic dysfunction-associated steatotic liver illness. Clin. Mol. Hepatol. 31, S32–S50 (2025).
Graupera, I. et al. Prevalence of liver fibrosis within the common inhabitants (the LiverDisplay venture): a multinational European cohort research. Lancet 407, 1448–1458 (2026). This potential research offers knowledge on the prevalence and danger components for liver fibrosis within the common inhabitants in Europe.
Stroes, A. R., Vos, M., Benninga, M. A. & Koot, B. G. P. Pediatric MASLD: present understanding and sensible method. Eur. J. Pediatr. 184, 29 (2024).
Rinella, M. E. et al. A multisociety Delphi consensus assertion on new fatty liver illness nomenclature. J. Hepatol. 79, 1542–1556 (2023). This multisociety worldwide consensus paper establishes the present terminology of MASLD and MASH, changing former definitions of NAFLD, NASH or MAFLD.
Llovet, J. M. et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and remedy. Nat. Rev. Gastroenterol. Hepatol. 20, 487–503 (2023).
Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal-Puig, A. & Bugianesi, E. Μetabolic dysfunction-associated steatotic liver illness: a situation of heterogeneous metabolic danger components, mechanisms and comorbidities requiring holistic remedy. Nat. Rev. Gastroenterol. Hepatol. 22, 314–328 (2025).
Targher, G., Byrne, C. D. & Tilg, H. MASLD: a systemic metabolic dysfunction with cardiovascular and malignant problems. Gut 73, 691–702 (2024).
Brunt, E. M. et al. Complexity of ballooned hepatocyte characteristic recognition: defining a coaching atlas for synthetic intelligence-based imaging in NAFLD. J. Hepatol. 76, 1030–1041 (2022).
Ratziu, V. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver illness. Gastroenterology 128, 1898–1906 (2005).
Bedossa, P. et al. Histopathological algorithm and scoring system for analysis of liver lesions in morbidly overweight sufferers. Hepatology 56, 1751–1759 (2012).
Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver illness. Hepatology 41, 1313–1321 (2005).
Naoumov, N. V. et al. Digital pathology with synthetic intelligence analyses offers larger insights into treatment-induced fibrosis regression in NASH. J. Hepatol. 77, 1399–1409 (2022).
Ratziu, V. et al. Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: present standing and future instructions. J. Hepatol. 80, 335–351 (2024).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO medical observe pointers on the administration of metabolic dysfunction-associated steatotic liver illness (MASLD). J. Hepatol. (2024). This multidisciplinary worldwide guideline offers evidence-based suggestions on case discovering, prognosis, danger stratification and remedy of MASLD.
Anstee, Q. M. et al. Prognostic utility of Fibrosis-4 Index for danger of subsequent liver and cardiovascular occasions, and all-cause mortality in people with weight problems and/or kind 2 diabetes: a longitudinal cohort research. Lancet Reg. Health Eur. 36, 100780 (2024).
Loosen, S. H. et al. An elevated FIB-4 rating predicts liver most cancers growth: a longitudinal evaluation from 29,999 sufferers with NAFLD. J. Hepatol. 76, 247–248 (2022).
Mózes, F. E. et al. Performance of non-invasive assessments and histology for the prediction of medical outcomes in sufferers with non-alcoholic fatty liver illness: a person participant knowledge meta-analysis. Lancet Gastroenterol. Hepatol. 8, 704–713 (2023).
Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver illness (the LITMUS venture): a comparative diagnostic accuracy research. Lancet Gastroenterol. Hepatol. 8, 714–725 (2023).
Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, heart problems or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 330–344 (2013).
Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392, 2089–2099 (2025). This section III trial demonstrates histological enchancment of MASH and fibrosis with weekly 2.4 mg semaglutide over 72 weeks, resulting in accelerated approval on this indication.
Sanyal, A. J. et al. A section 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med. 391, 311–319 (2024).
Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 391, 299–310 (2024).
Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
Harrison, S. A. et al. A section 3, randomized, managed trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497–509 (2024). This section III trial offers proof that resmetirom improves MASH decision and fibrosis enchancment in MASH after 52 weeks, resulting in accelerated approval on this indication.
Verrastro, O. et al. Bariatric-metabolic surgical procedure versus way of life intervention plus finest medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 401, 1786–1797 (2023). This potential trial demonstrates the efficacy of bariatric surgical procedure on liver histology for people with early-stage MASH.
Liu, H., Lefere, S., Guillot, A., Zheng, M. H. & Tacke, F. Bariatric surgical procedure for metabolic dysfunction-associated steatotic liver illness (MASLD): present data of mechanisms. Hepatology (2025).
Aminian, A. et al. Long-term liver outcomes after metabolic surgical procedure in compensated cirrhosis as a result of metabolic dysfunction-associated steatohepatitis. Nat. Med. 31, 988–995 (2025).
Gallage, S. et al. Molecular mechanisms and pathogenesis of MASH. Nature (within the press).
Abul-Husn, N. S. et al. A protein-truncating HSD17B13 variant and safety from persistent liver illness. N. Engl. J. Med. 378, 1096–1106 (2018).
Anstee, Q. M. et al. Genome-wide affiliation research of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J. Hepatol. 73, 505–515 (2020).
Kozlitina, J. et al. Exome-wide affiliation research identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver illness. Nat. Genet. 46, 352–356 (2014).
Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver illness. Nat. Genet. 40, 1461–1465 (2008).
Raverdy, V. et al. Data-driven cluster evaluation identifies distinct kinds of metabolic dysfunction-associated steatotic liver illness. Nat. Med. 30, 3624–3633 (2024).
Jamialahmadi, O. et al. Partitioned polygenic danger scores establish distinct kinds of metabolic dysfunction-associated steatotic liver illness. Nat. Med. 30, 3614–3623 (2024).
Ding, J. et al. Integrative multiomic evaluation identifies distinct molecular subtypes of NAFLD in a Chinese inhabitants. Sci. Transl. Med. 16, eadh9940 (2024).
Cherubini, A. et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver illness susceptibility in ladies. Nat. Med. 29, 2643–2655 (2023).
Bianco, C. et al. Non-invasive stratification of hepatocellular carcinoma danger in non-alcoholic fatty liver utilizing polygenic danger scores. J. Hepatol. 74, 775–782 (2021).
Chen, V. L. et al. Genetic danger accentuates dietary results on hepatic steatosis, irritation and fibrosis in a population-based cohort. J. Hepatol. 81, 379–388 (2024).
De Vincentis, A. et al. A polygenic danger rating to refine danger stratification and prediction for extreme liver illness by medical fibrosis scores. Clin. Gastroenterol. Hepatol. 20, 658–673 (2022).
Liu, Y. L. et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an elevated danger of non-alcoholic fatty liver illness related hepatocellular carcinoma. J. Hepatol. 61, 75–81 (2014).
Valenti, L. et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in sufferers with nonalcoholic fatty liver illness. Hepatology 51, 1209–1217 (2010).
Liu, Y. L. et al. TM6SF2 rs58542926 influences hepatic fibrosis development in sufferers with non-alcoholic fatty liver illness. Nat. Commun. 5, 4309 (2014).
Donati, B. et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic people. Sci. Rep. 7, 4492 (2017).
Teo, Okay. et al. rs641738C>T close to MBOAT7 is related to liver fats, ALT and fibrosis in NAFLD: a meta-analysis. J. Hepatol. 74, 20–30 (2021).
Du, M. et al. Cross-trait genomic modeling reveals the polygenic structure and systemic affect of MASLD. Sci. Adv. 12, eaeb5665 (2026).
Liu, Z. et al. Population stratification utilizing MASLD polygenic danger rating improves extreme liver illness prediction by medical fibrosis scores. Dig. Liver Dis. 57, 1819–1825 (2025).
Vilar-Gomez, E. et al. Genetic and non-genetic drivers of histological development and regression in MASLD. J. Hepatol. 84, 502–516 (2026).
Puengel, T. & Tacke, F. Pharmacotherapeutic choices for metabolic dysfunction-associated steatotic liver illness: the place are we right this moment? Expert Opin. Pharmacother. 25, 1249–1263 (2024).
Krag, A., Tacke, F., Israelsen, M. & Younossi, Z. M. Is liver steatosis a illness or the emperor’s new garments? J. Hepatol. 84, 993–1001 (2026).
Cheung, A. et al. Defining enchancment in nonalcoholic steatohepatitis for remedy trial endpoints: suggestions from the Liver Forum. Hepatology 70, 1841–1855 (2019).
Sanyal, A. J. et al. Endpoints and medical trial design for nonalcoholic steatohepatitis. Hepatology 54, 344–353 (2011).
Anania, F. A. et al. Non-invasive assessments: establishing efficacy for metabolic dysfunction-associated steatohepatitis past the biopsy—present views from the Division of Hepatology and Nutrition, US Food and Drug Administration. Hepatology (2025).
Loomba, R., Ratziu, V. & Harrison, S. A. Expert panel assessment to match FDA and EMA steerage on drug growth and endpoints in nonalcoholic steatohepatitis. Gastroenterology 162, 680–688 (2022).
Harrison, S. A. et al. Resmetirom for nonalcoholic fatty liver illness: a randomized, double-blind, placebo-controlled section 3 trial. Nat. Med. 29, 2919–2928 (2023).
US Food and Drug Administration. FDA approves first remedy for sufferers with liver scarring as a result of fatty liver illness. FDA (2024).
US Food and Drug Administration. FDA approves remedy for severe liver illness often called ‘MASH’. FDA (2025).
Chen, V. L. et al. Resmetirom remedy for metabolic dysfunction-associated steatotic liver illness: October 2024 updates to AASLD observe steerage. Hepatology 81, 312–320 (2025).
Aminian, A. et al. Association of bariatric surgical procedure with main antagonistic liver and cardiovascular outcomes in sufferers with biopsy-proven nonalcoholic steatohepatitis. JAMA 326, 2031–2042 (2021).
Petersen, Okay. F. et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by reasonable weight discount in sufferers with kind 2 diabetes. Diabetes 54, 603–608 (2005).
Taylor, R. et al. Remission of human kind 2 diabetes requires lower in liver and pancreas fats content material however relies upon capability for β cell restoration. Cell Metab. 28, 547–556.e3 (2018).
Vilar-Gomez, E. et al. Weight loss by way of way of life modification considerably reduces options of nonalcoholic steatohepatitis. Gastroenterology 149, 367–378.e5 (2015). This potential trial confirms the efficacy of rigorous way of life administration in sufferers with MASH, displaying that 10% weight reduction over 1 12 months associates with liver fibrosis regression.
Clifton, Okay. Okay., Ma, C. X., Fontana, L. & Peterson, L. L. Intermittent fasting within the prevention and remedy of most cancers. CA Cancer J. Clin. 71, 527–546 (2021).
Minciuna, I., Gallage, S., Heikenwalder, M., Zelber-Sagi, S. & Dufour, J. F. Intermittent fasting—the long run remedy in NASH sufferers? Hepatology 78, 1290–1305 (2023).
Gallage, S. et al. A 5:2 intermittent fasting routine ameliorates NASH and fibrosis and blunts HCC growth through hepatic PPARα and PCK1. Cell Metab. 36, 1371–1393.e7 (2024).
Holmer, M. et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat food regimen—a randomised managed trial. JHEP Rep. 3, 100256 (2021).
Wang, Y. Y., Tian, F., Qian, X. L., Ying, H. M. & Zhou, Z. F. Effect of 5:2 intermittent fasting food regimen versus each day calorie restriction consuming on metabolic-associated fatty liver illness—a randomized managed trial. Front. Nutr. 11, 1439473 (2024).
Wilkinson, M. J. et al. Ten-hour time-restricted consuming reduces weight, blood strain, and atherogenic lipids in sufferers with metabolic syndrome. Cell Metab. 31, 92–104.e5 (2020).
Feehan, J. et al. Time-restricted fasting improves liver steatosis in non-alcoholic fatty liver illness—a single blinded crossover trial. Nutrients 15, 4870 (2023).
Kord-Varkaneh, H., Salehi-Sahlabadi, A., Tinsley, G. M., Santos, H. O. & Hekmatdoost, A. Effects of time-restricted feeding (16/8) mixed with a low-sugar food regimen on the administration of non-alcoholic fatty liver illness: a randomized managed trial. Nutrition 105, 111847 (2023).
Oh, J. H. et al. Efficacy and security of time-restricted consuming in metabolic dysfunction-associated steatotic liver illness. J. Hepatol. 83, 1256–1265 (2025).
Wei, X. et al. Effects of time-restricted consuming on nonalcoholic fatty liver illness: the TREATY-FLD randomized medical trial. JAMA Netw. Open 6, e233513 (2023).
Scragg, J. et al. Feasibility of a really low calorie food regimen to realize a sustainable 10% weight reduction in sufferers with nonalcoholic fatty liver illness. Clin. Transl. Gastroenterol. 11, e00231 (2020).
Houghton, D. et al. Exercise reduces liver lipids and visceral adiposity in sufferers with nonalcoholic steatohepatitis in a randomized managed trial. Clin. Gastroenterol. Hepatol. 15, 96–102.e3 (2017).
Mucinski, J. M. et al. Histological enhancements following power restriction and train: the position of insulin resistance in decision of MASH. J. Hepatol. 81, 781–793 (2024).
Ezpeleta, M. et al. Effect of alternate day fasting mixed with cardio train on non-alcoholic fatty liver illness: a randomized managed trial. Cell Metab. 35, 56–70.e3 (2023).
Lassailly, G. et al. Resolution of metabolic dysfunction-associated steatohepatitis with no worsening of fibrosis after bariatric surgical procedure improves 15-year survival: a potential cohort research. Clin. Gastroenterol. Hepatol. 23, 1567–1576.e9 (2025).
Patton, H., Heimbach, J. & McCullough, A. AGA medical observe replace on bariatric surgical procedure in cirrhosis: knowledgeable assessment. Clin. Gastroenterol. Hepatol. 19, 436–445 (2021).
Temime, V. et al. Outcomes of bariatric surgical procedure within the setting of compensated superior persistent liver illness related to clinically important portal hypertension: a multicenter, retrospective, cohort research on feasibility and security. Int. J. Surg. 110, 3562–3570 (2024).
Larson, E. L. et al. Simultaneous liver transplant and sleeve gastrectomy offers sturdy weight reduction, improves metabolic syndrome and reduces allograft steatosis. J. Hepatol. 83, 729–737 (2025).
Pais, R. et al. Persistence of extreme liver fibrosis regardless of substantial weight reduction with bariatric surgical procedure. Hepatology 76, 456–468 (2022).
Tacke, F., Puengel, T., Loomba, R. & Friedman, S. L. An built-in view of anti-inflammatory and antifibrotic targets for the remedy of NASH. J. Hepatol. 79, 552–566 (2023).
Wirth, E. Okay., Puengel, T., Spranger, J. & Tacke, F. Thyroid hormones as a illness modifier and therapeutic goal in nonalcoholic steatohepatitis. Expert Rev. Endocrinol. Metab. 17, 425–434 (2022).
Kelly, M. J. et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a extremely selective thyroid hormone receptor β agonist in medical trials for the remedy of dyslipidemia. J. Med. Chem. 57, 3912–3923 (2014).
Taub, R. et al. Lipid reducing in wholesome volunteers handled with a number of doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis 230, 373–380 (2013).
Dubois, V., Lefebvre, P., Staels, B. & Eeckhoute, J. Nuclear receptors: pathophysiological mechanisms and drug targets in liver illness. Gut 73, 1562–1569 (2024).
Staels, B., Butruille, L. & Francque, S. Treating NASH by concentrating on peroxisome proliferator-activated receptors. J. Hepatol. 79, 1302–1316 (2023).
Lefere, S. et al. Differential results of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J. Hepatol. 73, 757–770 (2020).
Francque, S. et al. Nonalcoholic steatohepatitis: the position of peroxisome proliferator-activated receptors. Nat. Rev. Gastroenterol. Hepatol. 18, 24–39 (2021).
Francque, S. M. et al. A randomized, managed trial of the pan-PPAR agonist lanifibranor in NASH. N. Engl. J. Med. 385, 1547–1558 (2021).
Adorini, L. & Trauner, M. FXR agonists in NASH remedy. J. Hepatol. 79, 1317–1331 (2023).
Sanyal, A. J. et al. Results from a brand new efficacy and security evaluation of the REGENERATE trial of obeticholic acid for remedy of pre-cirrhotic fibrosis as a result of non-alcoholic steatohepatitis. J. Hepatol. 79, 1110–1120 (2023).
Younossi, Z. M. et al. Obeticholic acid for the remedy of non-alcoholic steatohepatitis: interim evaluation from a multicentre, randomised, placebo-controlled section 3 trial. Lancet 394, 2184–2196 (2019). This section III trial offers a optimistic interim evaluation for histological finish factors in MASH, however obeticholic acid in the end didn’t attain standards for regulatory approval.
Goetz, R. et al. Molecular insights into the klotho-dependent, endocrine mode of motion of fibroblast development issue 19 subfamily members. Mol. Cell. Biol. 27, 3417–3428 (2007).
Ogawa, Y. et al. βKlotho is required for metabolic exercise of fibroblast development issue 21. Proc. Natl Acad. Sci. USA 104, 7432–7437 (2007).
Ornitz, D. M. & Itoh, N. The fibroblast development issue signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4, 215–266 (2015).
Kharitonenkov, A. et al. FGF-21/FGF-21 receptor interplay and activation is decided by βKlotho. J. Cell. Physiol. 215, 1–7 (2008).
Kurosu, H. et al. Tissue-specific expression of betaKlotho and fibroblast development issue (FGF) receptor isoforms determines metabolic exercise of FGF19 and FGF21. J. Biol. Chem. 282, 26687–26695 (2007).
Yie, J. et al. FGF21 N- and C-termini play totally different roles in receptor interplay and activation. FEBS Lett. 583, 19–24 (2009).
Lee, J. H. et al. An engineered FGF21 variant, LY2405319, can stop non-alcoholic steatohepatitis by enhancing hepatic mitochondrial perform. Am. J. Transl. Res. 8, 4750–4763 (2016).
Tanaka, N. et al. Role of fibroblast development issue 21 within the early stage of NASH induced by methionine- and choline-deficient food regimen. Biochim. Biophys. Acta 1852, 1242–1252 (2015).
Xu, J. et al. Fibroblast development issue 21 reverses hepatic steatosis, will increase power expenditure, and improves insulin sensitivity in diet-induced overweight mice. Diabetes 58, 250–259 (2009).
Singhal, G. et al. Deficiency of fibroblast development issue 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long run obesogenic food regimen. Mol. Metab. 13, 56–66 (2018).
Le, C. T., Nguyen, G., Park, S. Y., Choi, D. H. & Cho, E. H. LY2405319, an analog of fibroblast development issue 21 ameliorates α-smooth muscle actin manufacturing by way of inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice. PLoS ONE 13, e0192146 (2018).
Yu, Y. et al. Fibroblast development issue 21 (FGF21) inhibits macrophage-mediated irritation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int. Immunopharmacol. 38, 144–152 (2016).
Harrison, S. A., Rolph, T., Knott, M. & Dubourg, J. FGF21 agonists: an rising therapeutic for metabolic dysfunction-associated steatohepatitis and past. J. Hepatol. 81, 562–576 (2024).
Loomba, R. et al. Pegbelfermin in sufferers with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized section 2b research. Clin. Gastroenterol. Hepatol. 22, 102–112.e9 (2024).
Harrison, S. A. et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, section 2b trial. Lancet Gastroenterol. Hepatol. 8, 1080–1093 (2023).
Noureddin, M. et al. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week outcomes from a multicentre, randomised, double-blind, placebo-controlled, section 2b trial. Lancet 406, 719–730 (2025).
Noureddin, M. et al. Efruxifermin in compensated liver cirrhosis attributable to MASH. N. Engl. J. Med. 392, 2413–2424 (2025). This section IIb trial demonstrates a fibrosis regression in MASH–cirrhosis, utilizing the FGF21 analogue efruxifermin for 96 weeks.
Noureddin, M. et al. Efimosfermin alfa (BOS-580) as soon as monthly in folks with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: outcomes from a 24-week, randomised, double-blind, placebo-controlled, section 2 trial. Lancet 407, 794–804 (2026).
Loomba, R. et al. Randomized, managed trial of the FGF21 analogue pegozafermin in NASH. N. Engl. J. Med. 389, 998–1008 (2023).
Esler, W. P. & Cohen, D. E. Pharmacologic inhibition of lipogenesis for the remedy of NAFLD. J. Hepatol. 80, 362–377 (2024).
Ratziu, V. et al. Aramchol in sufferers with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled section 2b trial. Nat. Med. 27, 1825–1835 (2021).
Loomba, R. et al. Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): outcomes of a 51-week, multicentre, randomised, double-blind, placebo-controlled, section 2 trial. Lancet 406, 821–831 (2025).
Wong, V. W. et al. Efficacy and security of ervogastat alone and together with clesacostat in sufferers with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): outcomes from a section 2, randomised, double-blind, double-dummy research. Lancet Gastroenterol. Hepatol. 10, 924–940 (2025).
Amin, N. B. et al. Efficacy and security of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the section II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (metabolic interventions to resolve NASH with fibrosis) research. BMJ Open 12, e056159 (2022).
Mantovani, A., Byrne, C. D. & Targher, G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for remedy of non-alcoholic fatty liver illness: a scientific assessment. Lancet Gastroenterol. Hepatol. 7, 367–378 (2022).
Lin, J. et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo managed trial. BMJ 389, e083735 (2025).
Lindén, D. & Romeo, S. Therapeutic alternatives for the remedy of NASH with genetically validated targets. J. Hepatol. 79, 1056–1064 (2023).
Armisen, J. et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the remedy of MASH in 148M homozygous contributors: two randomized section I trials. J. Hepatol. 83, 31–42 (2025).
Newsome, P. N. & Ambery, P. Incretins (GLP-1 receptor agonists and twin/triple agonists) and the liver. J. Hepatol. 79, 1557–1565 (2023).
Wong, C. Okay. & Drucker, D. J. Antiinflammatory actions of glucagon-like peptide-1-based therapies past metabolic advantages. J. Clin. Invest. 135, e194751 (2025).
Armstrong, M. J. et al. Liraglutide security and efficacy in sufferers with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled section 2 research. Lancet 387, 679–690 (2016).
Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113–1124 (2021).
Loomba, R. et al. Semaglutide 2.4 mg as soon as weekly in sufferers with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled section 2 trial. Lancet Gastroenterol. Hepatol. 8, 511–522 (2023).
Meyhöfer, S. M. et al. Semaglutide on liver fibrosis and coronary heart outcomes in sufferers at excessive danger of liver fibrosis: a prespecified evaluation of the SELECT randomized trial. Nat. Med. 32, 1686–1693 (2026). This prespecified evaluation of a giant potential trial utilizing 2.4 mg semaglutide signifies advantages for cardiovascular outcomes in people with presumed MASLD or MASH.
Deanfield, J. et al. Semaglutide and cardiovascular outcomes by baseline and adjustments in adiposity measurements: a prespecified evaluation of the SELECT trial. Lancet 406, 2257–2268 (2025).
Gonzalez-Rellan, M. J. et al. The weight-loss-independent hepatoprotective advantages of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors. Cell Metab. (2026).
Shankar, S. S. et al. Safety and efficacy of novel incretin co-agonist cotadutide in biopsy-proven noncirrhotic MASH with fibrosis. Clin. Gastroenterol. Hepatol. 22, 1847–1857.e11 (2024).
Romero-Gómez, M. et al. A section IIa active-comparator-controlled research to guage the efficacy and security of efinopegdutide in sufferers with non-alcoholic fatty liver illness. J. Hepatol. 79, 888–897 (2023).
Harrison, S. A. et al. Effect of pemvidutide, a GLP-1/glucagon twin receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled research. J. Hepatol. (2024).
Noureddin, M. et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week outcomes from a multicentre, randomised, double-blind, section 2b research. Lancet 406, 2644–2655 (2025).
Sanyal, A. J. et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver illness: a randomized section 2a trial. Nat. Med. 30, 2037–2048 (2024).
Jara, M. et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat. Med. 31, 3128–3140 (2025).
Bansal, M. B. et al. Semaglutide remedy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD observe steerage. Hepatology (2025).
Guillot, A. & Tacke, F. Liver macrophages revisited: the increasing universe of versatile responses in a spatiotemporal context. Hepatol. Commun. 8, e0491 (2024).
Ratziu, V. et al. Cenicriviroc remedy for adults with nonalcoholic steatohepatitis and fibrosis: ultimate evaluation of the section 2b CENTAUR research. Hepatology 72, 892–905 (2020).
Anstee, Q. M. et al. Cenicriviroc lacked efficacy to deal with liver fibrosis in nonalcoholic steatohepatitis: AURORA section III randomized research. Clin. Gastroenterol. Hepatol. 22, 124–134.e1 (2024).
Schwabe, R. F., Tacke, F., Sugimoto, A. & Friedman, S. L. Antifibrotic therapies for metabolic dysfunction-associated steatotic liver illness. JHEP Rep. 7, 101421 (2025).
Harrison, S. A. et al. Selonsertib for sufferers with bridging fibrosis or compensated cirrhosis as a result of NASH: outcomes from randomized section III STELLAR trials. J. Hepatol. 73, 26–39 (2020).
Dwyer, B. J., Macmillan, M. T., Brennan, P. N. & Forbes, S. J. Cell remedy for superior liver ailments: restore or rebuild. J. Hepatol. 74, 185–199 (2021).
Brennan, P. N. et al. Autologous macrophage remedy for liver cirrhosis: a section 2 open-label randomized managed trial. Nat. Med. 31, 979–987 (2025).
Moroni, F. et al. Safety profile of autologous macrophage remedy for liver cirrhosis. Nat. Med. 25, 1560–1565 (2019).
Dai, H. et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical fashions. J. Hepatol. 80, 913–927 (2024).
Malehmir, M. et al. Platelet GPIbα is a mediator and potential interventional goal for NASH and subsequent liver most cancers. Nat. Med. 25, 641–655 (2019).
Ramadori, P., Klag, T., Malek, N. P. & Heikenwalder, M. Platelets in persistent liver illness, from bench to bedside. JHEP Rep. 1, 448–459 (2019).
Baratta, F. et al. Platelet thromboxane B2 overproduction related to liver fibrosis severity in sufferers with MASLD. Thromb. Res. 257, 109540 (2025).
Horn, P. & Tacke, F. Metabolic reprogramming in liver fibrosis. Cell Metab. 36, 1439–1455 (2024).
Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127–132 (2020).
Yashaswini, C. N. et al. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis. J. Hepatol. 81, 207–217 (2024).
Illert, A. L. et al. The German Network for Personalized Medicine to reinforce affected person care and translational analysis. Nat. Med. 29, 1298–1301 (2023).
Loomba, R. et al. Combination therapies together with cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73, 625–643 (2021).
Loomba, R. et al. Denifanstat for the remedy of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, section 2b trial. Lancet Gastroenterol. Hepatol. 9, 1090–1100 (2024).
Harrison, S. A. et al. Aldafermin in sufferers with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, section 2b trial. Lancet Gastroenterol. Hepatol. 7, 603–616 (2022).
Harrison, S. A. et al. A section IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH. J. Hepatol. 83, 293–303 (2025).
Harrison, S. A. et al. Design of the section 3 MAESTRO medical program to guage resmetirom for the remedy of nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther. 59, 51–63 (2024).
Lian, B. Results from the 52-week section 2b VOYAGE trial of VK2809 in sufferers with biopsy-confirmed non-alcoholic steatohepatitis and fibrosis: a randomized, placebo-controlled trial [The Liver Meeting: San Diego, 2024; Late Breaker #5016]. Hepatology 80, S1–S2011 (2024).
Noureddin, M. et al. TERN-501 monotherapy and mixture remedy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized section 2a DUET trial. Nat. Med. 31, 2297–2305 (2025).
Harrison, S. A. et al. Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in sufferers with NASH: a section II randomized placebo-controlled trial (DESTINY-1). J. Hepatol. 78, 914–925 (2023).
Siddiqui, M. S. et al. A section 2 double blinded, randomized managed trial of saroglitazar in sufferers with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 19, 2670–2672 (2021).
Harrison, S. A. et al. A randomized, placebo-controlled trial of emricasan in sufferers with NASH and F1-F3 fibrosis. J. Hepatol. 72, 816–827 (2020).
Harrison, S. A. et al. Simtuzumab is ineffective for sufferers with bridging fibrosis or compensated cirrhosis attributable to nonalcoholic steatohepatitis. Gastroenterology 155, 1140–1153 (2018).
Lazarus, J. V. et al. The international NAFLD coverage assessment and preparedness index: are international locations prepared to deal with this silent public well being problem? J. Hepatol. 76, 771–780 (2022).
Davison, B. A. et al. Suboptimal reliability of liver biopsy analysis has implications for randomized medical trials. J. Hepatol. 73, 1322–1332 (2020).
Zoncapè, M., Liguori, A. & Tsochatzis, E. A. Non-invasive testing and risk-stratification in sufferers with MASLD. Eur. J. Intern. Med. 122, 11–19 (2024).
Anstee, Q. M., Castera, L. & Loomba, R. Impact of non-invasive biomarkers on hepatology observe: previous, current and future. J. Hepatol. 76, 1362–1378 (2022).
Taylor, R. S. et al. Association between fibrosis stage and outcomes of sufferers with nonalcoholic fatty liver illness: a scientific assessment and meta-analysis. Gastroenterology 158, 1611–1625.e12 (2020).
Sterling, R. Okay. et al. Development of a easy noninvasive index to foretell important fibrosis in sufferers with HIV/HCV coinfection. Hepatology 43, 1317–1325 (2006).
Boyle, M. et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver illness. JHEP Rep. 1, 188–198 (2019).
Mak, A. L. et al. Systematic assessment with meta-analysis: diagnostic accuracy of PRO-C3 for hepatic fibrosis in sufferers with non-alcoholic fatty liver illness. Biomedicines 9, 1920 (2021).
Rosenberg, W. M. et al. Serum markers detect the presence of liver fibrosis: a cohort research. Gastroenterology 127, 1704–1713 (2004).
Daniels, S. J. et al. ADAPT: an algorithm incorporating PRO-C3 precisely identifies sufferers with NAFLD and superior fibrosis. Hepatology 69, 1075–1086 (2019).
Mózes, F. E. et al. Diagnostic accuracy of non-invasive assessments for superior fibrosis in sufferers with NAFLD: a person affected person knowledge meta-analysis. Gut 71, 1006–1019 (2022).
Pavlides, M. et al. Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study. Nat. Med. (2026).
Vali, Y. et al. Enhanced liver fibrosis check for the non-invasive prognosis of fibrosis in sufferers with NAFLD: a scientific assessment and meta-analysis. J. Hepatol. 73, 252–262 (2020).
Vali, Y. et al. FibroTest for evaluating fibrosis in non-alcoholic fatty liver illness sufferers: a scientific assessment and meta-analysis. J. Clin. Med. 10, 2415 (2021).
Van Dijk, A. M. et al. Systematic assessment with meta-analyses: diagnostic accuracy of FibroMeter assessments in sufferers with non-alcoholic fatty liver illness. J. Clin. Med. 10, 2910 (2021).
Sanyal, A. J. et al. Diagnostic efficiency of circulating biomarkers for non-alcoholic steatohepatitis. Nat. Med. 29, 2656–2664 (2023).
Rinella, M. E. et al. AASLD observe steerage on the medical evaluation and administration of nonalcoholic fatty liver illness. Hepatology 77, 1797–1835 (2023).
Fichez, J. et al. Non-invasive assessments for fibrotic MASH for lowering display screen failure in therapeutic trials. JHEP Rep. 7, 101351 (2025).
Yip, T. C. et al. Prognostic efficiency of the two-step medical care pathway in metabolic dysfunction-associated steatotic liver illness. J. Hepatol. 83, 304–314 (2025).
Govaere, O. et al. Transcriptomic profiling throughout the nonalcoholic fatty liver illness spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci. Transl. Med. 12, eaba4448 (2020).
Kozumi, Okay. et al. Transcriptomics establish thrombospondin-2 as a biomarker for NASH and superior liver fibrosis. Hepatology 74, 2452–2466 (2021).
Hoang, S. A. et al. Gene expression predicts histological severity and divulges distinct molecular profiles of nonalcoholic fatty liver illness. Sci. Rep. 9, 12541 (2019).
Govaere, O. et al. A proteo-transcriptomic map of non-alcoholic fatty liver illness signatures. Nat. Metab. 5, 572–578 (2023).
Corey, Okay. E. et al. ADAMTSL2 protein and a soluble biomarker signature establish at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD. J. Hepatol. 76, 25–33 (2022).
Sanyal, A. J. et al. Defining the serum proteomic signature of hepatic steatosis, irritation, ballooning and fibrosis in non-alcoholic fatty liver illness. J. Hepatol. 78, 693–703 (2023).
Indira Chandran, V. et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in sufferers with elevated liver stiffness. Hepatology 77, 558–572 (2023).
Masoodi, M. et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic assessments. Nat. Rev. Gastroenterol. Hepatol. 18, 835–856 (2021).
Noureddin, M. et al. Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis rating (MASEF). Hepatology 79, 135–148 (2024).
Harrison, S. A. et al. A blood-based biomarker panel (NIS4) for non-invasive prognosis of non-alcoholic steatohepatitis and liver fibrosis: a potential derivation and international validation research. Lancet Gastroenterol. Hepatol. 5, 970–985 (2020).
Johnson, Okay. et al. Increased serum miR-193a-5p throughout non-alcoholic fatty liver illness development: diagnostic and mechanistic relevance. JHEP Rep. 4, 100409 (2022).
Harrison, S. A. et al. NIS2+TM, an optimisation of the blood-based biomarker NIS4® expertise for the detection of at-risk NASH: a potential derivation and validation research. J. Hepatol. 79, 758–767 (2023).
This web page was created programmatically, to learn the article in its authentic location you possibly can go to the hyperlink bellow:
https://www.nature.com/articles/s41586-026-10672-8
and if you wish to take away this text from our website please contact us
